Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL | Q9Y232 | 1/20 | 0.42 |
| ▸ | IAPP | P10997 | 4/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902810 | 0.90 | CYP4F2 (0.54) | CDYLIAPPCYP4F2CYP4A11KDM4E | |
| SCHEMBL5598458 | 0.90 | MAPK1 (0.46) | CDYLIAPPCYP4F2CYP4A11KDM4E | |
| SCHEMBL6904647 | 0.82 | CYP4F2 (0.51) | IAPPCYP4F2CYP4A11TSHRALDH1A1 | |
| SCHEMBL5599028 | 0.82 | TSHR (0.41) | TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL5598810 | 0.80 | IAPP (0.51) | CDYLIAPPCYP4F2CYP4A11KDM4E | |
| SCHEMBL6870041 | 0.79 | TSHR (0.53) | IAPPTSHRALOX5 | |
| SCHEMBL6902265 | 0.79 | CYP4F2 (0.56) | IAPPCYP4F2CYP4A11KDM4ETSHR | |
| SCHEMBL5598758 | 0.77 | MAPK1 (0.46) | TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL13410217 | 0.76 | TSHR (0.50) | IAPPTSHRALOX5 | |
| SCHEMBL5598497 | 0.76 | TSHR (0.44) | KDM4ETSHRMAPK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226946-B2 | Substituted phenol compounds useful for anesthesia and sedation | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20050032753-A1 | Substituted phenol compounds useful for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-10 | — | — | US | disclosed |
| US-6815555-B2 | CONTAINING AN ESTER, ANHYDRIDE, PHOSPHONATE OR THIOESTER GROUP | THERAVANCE, INC. | 2004-11-09 | — | — | US | disclosed |
| EP-1430017-A2 | SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION | Theravance, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030119790-A1 | Substituted phenol compounds useful for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003026632-A2 | SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032753-A1 | Substituted phenol compounds useful for anesthesia and sedation | OPRL1, PNMT, PPARG | CDYL 700/4885IAPP 4498/4885CYP4F2 532/4885 |
| US-20030119790-A1 | Substituted phenol compounds useful for anesthesia and sedation | OPRL1, PNMT, PPARG | CDYL 700/4885IAPP 4498/4885CYP4F2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.